Skip to main content

Table 4 Multivariate analysis of transplants outcomes

From: Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT

Variable

aGvHD II–IV

cGvHD

NRM

RI

LFS

OS

GRFS

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

Donor type

              

 MSD

1

 

1

 

1

 

1

 

1

 

1

 

1

 

 MUD

1.25 (0.73–2.13)

0.42

1.84 (1.02–3.34)

0.04

1.06 (0.47–2.38)

0.89

0.78 (0.38–1.57)

0.48

0.91 (0.54–1.55)

0.74

1.05 (0.57–1.94)

0,.7

1.02 (0.65–1.59)

0,.3

 Haplo

0.99 (0.62–1.57)

0.96

1.03 (0.59–1.79)

0.93

1.16 (0.6–2.25)

0.66

0.74 (0.43–1.28)

0.28

0.91 (0.59–1.39)

0.65

1.13 (0.68–1.86)

0.64

0.96 (0.66–1.4)

0.84

Patient’s age per 10 years1

1.01 (0.9–1.14)

0,83

1.03 (0.89–1.18)

0,72

1.3 (1.1–1.55)

0,002

0.95(0.81–1.11)

0,5

1.09 (0.97–1.22)

0,14

1.15 (1.02–1.31)

0,03

1.07 (0.97–1.18)

0,17

Patient’s gender

              

 Male

1

 

1

 

1

 

1

 

1

 

1

 

1

 

 Female

0.84 (0.59–1.19)

0.33

0.59 (0.4–0.87)

0.008

0.67 (0.41–1.09)

0.1

0.79 (0.5–1.24)

0.31

0.74 (0.53–1.03)

0.08

0.68 (0.47–1)

0.04

0.75 (0.56–0.99)

0.04

Karnofsky performance status

              

 Poor (< 90)

1

 

1

 

1

 

1

 

1

 

1

 

1

 

 Good (≥ 90)

1.12 (0.73–1.7)

0.61

0.65 (0.39–1.06)

0.09

0.78 (0.45–1.36)

0.55

1.2 (0.68–2.13)

0.53

0.94 (0.63–1.39)

0.75

0.82 (0.53–1.27)

0.38

1.03 (0.73–1.47))

0.86

Patient’s CMV serostatus

              

Negative

1

 

1

 

1

 

1

 

1

 

1

 

1

 

Positive

0.98 (0.66–1.44)

0.90

0.76 (0.5–1.17)

0.21

1.45 (0.78–2.71)

0.24

1.46 (0.85–2.52)

0.17

1.44 (0.95–2.17)

0.08

1.21 (0.77–1.91)

0.4

1.05 (0.75–1.46)

0.78

Cytogenetics

              

 Philadephia neg

1

 

1

 

1

 

1

 

1

 

1

 

1

 

 Philadephia pos

1.02 (0.7–1.47)

0.94

0.8 (0.53–1.21)

0.3

0.87 (0.52–1.43)

0.58

0.54 (0.32–0.9)

0.02

0.71 (0.5–1.02)

0.06

0.67 (0.45–1)

0.05

0.8 (0.59–1.09)

0.16

 Philadephia unknown

0.75 (0.43–1.31))

0.32

1.06 (0.57–1.94)

0.86

1.07 (0.5–2.29))

0.87

0.80 (0.43–1.49)

0.48

0.89 (0.54–1.46)

0.64

0.86 (0.49–1.52)

0.61

0,78 (0.5–1.22)

0.27

Type of conditioning

              

 Based on chemotherapy

1

 

1

 

1

 

1

 

1

 

1

 

1

 

 Based on TBI

1.17 (0.85–1.63)

0.34

0.79 (0.52–1.2)

0,.7

0.68 (0.41–1.13)

0.13

0.68 (0.45–1.05)

0.08

0.70 (0.51–0.98)

0.04

0.78 (0.53–1.14)

0.20

0.78 (0.58–1.03)

0.08

Year of transplant1

0.98 (0.91–1.07)

0.69

0.90 (0.81–0.99)

0.03

0.93 (0.83–1.04)

0.21

0.95 (0.85–1.05)

0.28

0.93 (0.86–1)

0.07

0.90 (0.82–0.98)

0.01

0.97 (0.91–1.04)

0,47

  1. Bold statistically significant variables for specific outcomes
  2. 1. Continuous variable
  3. GvHD, graft-versus-host disease; CI, confidence interval; NRM, non-relapse mortality; RI, relapse incidence; LFS, leukemia-free survival; OS, overall survival; GRFS, graft-versus-host disease and relapse-free survival; TBI, total body irradiation
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us